Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05645315 | Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 127 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04433494 | A Study of TY-302 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | TYK Medicines, IncINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05416710 | Universal Germline Testing in the Community(UNITY) | unknown | — | 1,000 | Invitae CorporationINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05638828 | A Study of RD14-01 in Patients With Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shen LinOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT04450901 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Y Biologics Inc.INDUSTRY | 3 | Dec 5, 2022 | clinicaltrials |
| NCT05637034 | 68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer | unknown | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05633719 | Multicenter, Prospective Observational Study for Early Diagnosis, and Development of Follow-up Protocol and Hearing Rehabilitation Program for Ototoxic Hearing Loss After Chemotherapy for Pediatric Solid Cancer | unknown | — | 300 | Seoul National University HospitalOTHER | 0 | Dec 1, 2022 | clinicaltrials |
| NCT04472858 | A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05205408 | A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 7 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05626764 | QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management | unknown | — | 3,000 | Hospices Civils de LyonOTHER | 4 | Nov 25, 2022 | clinicaltrials |
| NCT05623891 | Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT04976218 | TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors | unknown | Phase 1 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03792958 | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 19 | AnewPharmaINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05461287 | Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03774979 | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 193 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05609019 | A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 | 139 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03491631 | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05373147 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | unknown | Early Phase 1 | 21 | Shanghai Mengchao Cancer HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05198752 | A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Stemirna TherapeuticsINDUSTRY | 2 | Oct 17, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05522309 | FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors(FLIGHT) | unknown | Phase 1 | 37 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05150457 | Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | Binacea Pharma, Inc.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05457517 | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 49 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05539183 | Collection of Pleural Effusion Fluid | unknown | N/A | 50 | Universitair Ziekenhuis BrusselOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05534178 | Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients(PLANTOLOGY) | unknown | — | 2,500 | Vall d'Hebron Institute of OncologyOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT05530200 | PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. | unknown | Phase 2 | 56 | Second Affiliated Hospital of Soochow UniversityOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05527821 | Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors | unknown | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05528406 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation | unknown | Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Sep 6, 2022 | clinicaltrials |
| NCT03634982 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | unknown | Phase 1 | 133 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524194 | 6MW3511 in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 272 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05525559 | SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors(FIRST) | unknown | Phase 1 | 34 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05515185 | B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors | unknown | Early Phase 1 | 30 | The First People's Hospital of LianyungangOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT05508620 | A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 270 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05512780 | Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer | unknown | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05508373 | A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 72 | Suzhou Kebo Ruijun Biotechnology Co., LtdINDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05508659 | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 128 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT05435768 | PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors(PRaG 2X) | unknown | — | 51 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05505877 | Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 160 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04892498 | Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) | unknown | Phase 2 | 66 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05205421 | A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer | unknown | Phase 1 | 20 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05478785 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT03373656 | Vaccination for Children of H&O and Their Parents | unknown | N/A | 300 | Children's Cancer Group, ChinaNETWORK | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05432726 | Prediction of Chemotherapy Toxicity and Survival in Elderly Cancer Patients by CARG Score | unknown | — | 63 | Assiut UniversityOTHER | 0 | Jul 19, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2022source: clinicaltrials